simvastatin has been researched along with ciprofibrate in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (45.00) | 18.2507 |
| 2000's | 6 (30.00) | 29.6817 |
| 2010's | 4 (20.00) | 24.3611 |
| 2020's | 1 (5.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Infante, J; Infante, R; Qin, W; Wang, SR | 1 |
| Charmoillaux, M; Goudonnet, H; Mercenne, F; Mounié, J; Truchot, RC | 1 |
| Devuyst, O; Goffin, E; Pirson, Y; van Ypersele de Strihou, C | 1 |
| Baigts, F; Bruckert, E; De Gennes, JL; Malbecq, W | 1 |
| Athyros, VG; Boudoulas, H; Hatzikonstandinou, HA; Kontopoulos, AG; Mayroudi, MC; Papageorgiou, AA | 1 |
| Autier, P; Muls, E; Van Gaal, L; Vansant, G | 1 |
| Athyros, VG; Carina, MV; Didangelos, TP; Hatzikonstandinou, HA; Kontopoulos, AG; Kranitsas, DF; Papageorgiou, AA | 1 |
| Bruckert, E | 1 |
| Kvetnoi, IM; Martinsen, TC; Sandvik, AK; Schulze, B; Sylte, R; Waldum, HL | 1 |
| Athyros, VG; Kontopoulos, AG; Papageorgiou, AA | 1 |
| Athyros, VG; Athyrou, VV; Demitriadis, DS; Kontopoulos, AG; Papageorgiou, AA; Pehlivanidis, AN | 1 |
| Fujisaki, K; Itoh, Y; Maiguma, T; Makino, K; Oishi, R; Sasaguri, T; Takahashi-Yanaga, F; Teshima, D | 1 |
| Romaniv, S; Vecka, M; Zák, A; Zeman, M | 1 |
| Balice, M; Chironi, G; Del-Pino, M; Gariepy, J; Levenson, J; Simon, A | 1 |
| Hayakawa, EH; Kato, H; Nardone, GA; Usukura, J | 1 |
1 review(s) available for simvastatin and ciprofibrate
| Article | Year |
|---|---|
[Treatment of familial combined hyperlipidemia].
Topics: Clinical Protocols; Clofibric Acid; Fibric Acids; Gemfibrozil; Humans; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Lipids; Nicotinic Acids; Simvastatin | 1997 |
6 trial(s) available for simvastatin and ciprofibrate
| Article | Year |
|---|---|
Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia.
Topics: Anticholesteremic Agents; Bezafibrate; Cholesterol, LDL; Clofibric Acid; Fatty Acids, Volatile; Female; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipoproteins; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1995 |
Effects of simvastatin and ciprofibrate alone and in combination on lipid profile, plasma fibrinogen and low density lipoprotein particle structure and distribution in patients with familial combined hyperlipidaemia and coronary artery disease.
Topics: Adult; Analysis of Variance; Clofibric Acid; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Female; Fibric Acids; Fibrinogen; Follow-Up Studies; Humans; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Lipids; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Morbidity; Prospective Studies; Safety; Simvastatin; Survival Rate; Treatment Outcome; Ultracentrifugation | 1996 |
Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Cholesterol, LDL; Clofibric Acid; Drug Therapy, Combination; Female; Fibric Acids; Gemfibrozil; Humans; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin; Treatment Outcome | 1997 |
Statin-fibrate combinations in patients with combined hyperlipedemia.
Topics: Clofibric Acid; Coronary Disease; Drug Therapy, Combination; Fibric Acids; Follow-Up Studies; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type V; Hypolipidemic Agents; Myocardial Infarction; Pravastatin; Simvastatin; Stroke | 2001 |
Atorvastatin versus four statin-fibrate combinations in patients with familial combined hyperlipidaemia.
Topics: Adult; Aged; Atorvastatin; Clofibric Acid; Drug Therapy, Combination; Female; Fibric Acids; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Lipids; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrroles; Simvastatin; Time Factors | 2002 |
[Long-term hypolipidemic treatment of mixed hyperlipidemia with a combination of statins and fibrates].
Topics: Adult; Aged; Anticholesteremic Agents; Clofibric Acid; Drug Therapy, Combination; Female; Fenofibrate; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type V; Hypolipidemic Agents; Male; Middle Aged; Pravastatin; Simvastatin | 2003 |
13 other study(ies) available for simvastatin and ciprofibrate
| Article | Year |
|---|---|
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Regulation of HMG-CoA reductase, apoprotein-B and LDL receptor gene expression by the hypocholesterolemic drugs simvastatin and ciprofibrate in Hep G2, human and rat hepatocytes.
Topics: Acetates; Animals; Anticholesteremic Agents; Apolipoproteins B; Cell Line; Cholesterol; Clofibric Acid; Dose-Response Relationship, Drug; Fibric Acids; Gene Expression Regulation; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Liver; Lovastatin; Mevalonic Acid; Rats; Receptors, LDL; RNA, Messenger; Simvastatin | 1992 |
Comparative and simultaneous effects of simvastatin and ciprofibrate on plasma lipid parameters and upon hepatic drug metabolizing and peroxisome proliferation marker enzymes in the male Wistar rat.
Topics: Animals; Anticholesteremic Agents; Clofibric Acid; Fibric Acids; Hypolipidemic Agents; Lipids; Liver; Lovastatin; Male; Microbodies; Mixed Function Oxygenases; Rats; Simvastatin | 1991 |
Hypercholesterolemia treatment in a renal transplant patient.
Topics: Anticholesteremic Agents; Bezafibrate; Clofibric Acid; Female; Fenofibrate; Fibric Acids; Humans; Hypercholesterolemia; Kidney Transplantation; Lovastatin; Male; Middle Aged; Postoperative Complications; Simvastatin | 1994 |
Effects of initial BMI and on-treatment weight change on the lipid-lowering efficacy of fibrates.
Topics: Body Mass Index; Clofibric Acid; Female; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lipids; Lovastatin; Male; Middle Aged; Prospective Studies; Sex Factors; Simvastatin; Weight Loss | 1997 |
The effect of the peroxisome proliferator ciprofibrate on the gastric mucosa and particularly the gastrin cell.
Topics: Animals; Anticholesteremic Agents; Clofibric Acid; Female; Fibric Acids; Gastric Mucosa; Gastrins; Gene Expression; Histidine Decarboxylase; Hypolipidemic Agents; Lovastatin; Male; Microbodies; Rats; Rats, Inbred F344; Rats, Wistar; Simvastatin; Somatostatin; Species Specificity | 1998 |
Cell-specific toxicity of fibrates in human embryonal rhabdomyosarcoma cells.
Topics: Bezafibrate; Clofibrate; Clofibric Acid; Disease Models, Animal; Drug Synergism; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypolipidemic Agents; Receptors, Cytoplasmic and Nuclear; Reverse Transcriptase Polymerase Chain Reaction; Rhabdomyosarcoma, Embryonal; RNA, Messenger; Simvastatin; Time Factors; Transcription Factors; Tumor Cells, Cultured | 2003 |
Differential associations of statin and fibrate treatment with carotid arterial remodeling.
Topics: Adult; Atorvastatin; Bezafibrate; Body Mass Index; Carotid Arteries; Cholesterol, HDL; Clofibric Acid; Cohort Studies; Dyslipidemias; Fatty Acids, Monounsaturated; Female; Fenofibrate; Fibric Acids; Fluvastatin; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Male; Middle Aged; Multivariate Analysis; Pravastatin; Pyridines; Pyrroles; Risk Factors; Simvastatin; Treatment Outcome; Tunica Intima; Tunica Media; Ultrasonography | 2005 |
A prospective mechanism and source of cholesterol uptake by Plasmodium falciparum-infected erythrocytes co-cultured with HepG2 cells.
Topics: Anticholesteremic Agents; Cholesterol; Erythrocytes; Ezetimibe; Fibric Acids; Hep G2 Cells; Humans; Hypolipidemic Agents; Plasmodium falciparum; Simvastatin | 2021 |